AEs With BTKis

CE / CME

Multidisciplinary Perspectives on CLL-Related Symptoms and Managing Adverse Events With BTK Inhibitors

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: May 31, 2022

Expiration: May 30, 2023

Nichole Fisher
Nichole Fisher, RN, BSN
Nicole Lamanna
Nicole Lamanna, MD
Anthony J. Perissinotti
Anthony J. Perissinotti, PharmD, BCOP

Activity

Progress
1
Course Completed

In this focused activity, Nicole Lamanna, MD; Nichole Fisher, RN, BSN; and Anthony Perissinotti, PharmD, BCOP, review common symptoms related to chronic lymphocytic leukemia (CLL) and best practices in identifying and managing key adverse events (AEs) associated with BTK inhibitors in patients with CLL.

Clinical Care Options plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once prior to the discussion that informs the best choice and then again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following question.

If you are a practicing healthcare professional, how many patients with CLL do you provide care for in a typical month?

Currently, how confident are you in your ability to recognize and manage AEs with BTK inhibitors in patients with CLL? Please rate your confidence on a scale of 1 to 7, where 1 is not confident and 7 is very confident.